Clinical Research Directory
Browse clinical research sites, groups, and studies.
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
Sponsor: China Medical University Hospital
Summary
At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.
Official title: NMDA Receptor Modulation for the Treatment of Cognitive Impairment and Perceived Stress in Bipolar I Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2023-10-04
Completion Date
2027-12
Last Updated
2025-02-19
Healthy Volunteers
No
Conditions
Interventions
NMDAE
Use of an NMDA enhancer for the treatment of bipolar depression
Placebo Cap
Use of placebo as a comparator.
Locations (1)
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan